Outcomes of stereotactic body radiotherapy for bone oligometastases in older patients - A European multicenter cohort study - PubMed
6 hours ago
- #Bone metastases
- #SBRT
- #Older patients
- Study evaluates stereotactic body radiotherapy (SBRT) for bone oligometastases (BoM) in patients aged ≥70 compared to younger patients.
- No significant difference in local recurrence rates between age groups: 9.3% (<70 years) vs. 11.7% (≥70 years).
- Low rates of grade-3 adverse events (1.8% <70 years vs. 1.4% ≥70 years) and no grade-4/5 events observed.
- Fracture rates were low: 2.9% (<70 years) vs. 1.8% (≥70 years).
- Higher metastatic volume linked to worse outcomes (freedom from local recurrence, progression-free survival, overall survival).
- Better performance status associated with improved progression-free and overall survival; age was not a significant factor.
- SBRT is effective and well-tolerated in older patients with BoM, with no significant age-related differences in outcomes or side effects.